242 related articles for article (PubMed ID: 10626788)
21. Development of screening systems for drugs against human papillomavirus-associated cervical cancer: based on E6-E6AP binding.
Cho Y; Cho C; Joung O; Lee K; Park S; Yoon D
Antiviral Res; 2000 Sep; 47(3):199-206. PubMed ID: 10974372
[TBL] [Abstract][Full Text] [Related]
22. Sodium arsenite suppresses human papillomavirus-16 E6 gene and enhances apoptosis in E6-transfected human lymphoblastoid cells.
Chou RH; Huang H
J Cell Biochem; 2002; 84(3):615-24. PubMed ID: 11813266
[TBL] [Abstract][Full Text] [Related]
23. Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase.
Nakagawa S; Huibregtse JM
Mol Cell Biol; 2000 Nov; 20(21):8244-53. PubMed ID: 11027293
[TBL] [Abstract][Full Text] [Related]
24. Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6.
Camus S; Higgins M; Lane DP; Lain S
FEBS Lett; 2003 Feb; 536(1-3):220-4. PubMed ID: 12586367
[TBL] [Abstract][Full Text] [Related]
25. HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background.
Massimi P; Shai A; Lambert P; Banks L
Oncogene; 2008 Mar; 27(12):1800-4. PubMed ID: 17934525
[TBL] [Abstract][Full Text] [Related]
26. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells.
Hengstermann A; Linares LK; Ciechanover A; Whitaker NJ; Scheffner M
Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1218-23. PubMed ID: 11158620
[TBL] [Abstract][Full Text] [Related]
27. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6.
Freedman DA; Levine AJ
Mol Cell Biol; 1998 Dec; 18(12):7288-93. PubMed ID: 9819415
[TBL] [Abstract][Full Text] [Related]
28. Felis catus papillomavirus type-2 E6 binds to E6AP, promotes E6AP/p53 binding and enhances p53 proteasomal degradation.
Altamura G; Power K; Martano M; Degli Uberti B; Galiero G; De Luca G; Maiolino P; Borzacchiello G
Sci Rep; 2018 Dec; 8(1):17529. PubMed ID: 30510267
[TBL] [Abstract][Full Text] [Related]
29. Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells.
Beer-Romero P; Glass S; Rolfe M
Oncogene; 1997 Feb; 14(5):595-602. PubMed ID: 9053858
[TBL] [Abstract][Full Text] [Related]
30. Stepwise multipolyubiquitination of p53 by the E6AP-E6 ubiquitin ligase complex.
Masuda Y; Saeki Y; Arai N; Kawai H; Kukimoto I; Tanaka K; Masutani C
J Biol Chem; 2019 Oct; 294(41):14860-14875. PubMed ID: 31492752
[TBL] [Abstract][Full Text] [Related]
31. A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential.
Elbel M; Carl S; Spaderna S; Iftner T
Virology; 1997 Dec; 239(1):132-49. PubMed ID: 9426453
[TBL] [Abstract][Full Text] [Related]
32. Multiple regions of E6AP (UBE3A) contribute to interaction with papillomavirus E6 proteins and the activation of ubiquitin ligase activity.
Drews CM; Brimer N; Vande Pol SB
PLoS Pathog; 2020 Jan; 16(1):e1008295. PubMed ID: 31971989
[TBL] [Abstract][Full Text] [Related]
33. Pitx2a binds to human papillomavirus type 18 E6 protein and inhibits E6-mediated P53 degradation in HeLa cells.
Wei Q
J Biol Chem; 2005 Nov; 280(45):37790-7. PubMed ID: 16129685
[TBL] [Abstract][Full Text] [Related]
34. Characterization of the interactions of human papillomavirus type 16 E6 with p53 and E6-associated protein in insect and human cells.
Daniels PR; Sanders CM; Maitland NJ
J Gen Virol; 1998 Mar; 79 ( Pt 3)():489-99. PubMed ID: 9519827
[TBL] [Abstract][Full Text] [Related]
35. Surface plasmon resonance imaging protein arrays for analysis of triple protein interactions of HPV, E6, E6AP, and p53.
Ro HS; Koh BH; Jung SO; Park HK; Shin YB; Kim MG; Chung BH
Proteomics; 2006 Apr; 6(7):2108-11. PubMed ID: 16493710
[TBL] [Abstract][Full Text] [Related]
36. The DNA repair protein, O(6)-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein.
Srivenugopal KS; Ali-Osman F
Oncogene; 2002 Aug; 21(38):5940-5. PubMed ID: 12185595
[TBL] [Abstract][Full Text] [Related]
37. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300.
Zimmermann H; Degenkolbe R; Bernard HU; O'Connor MJ
J Virol; 1999 Aug; 73(8):6209-19. PubMed ID: 10400710
[TBL] [Abstract][Full Text] [Related]
38. C-Abl as a modulator of p53.
Levav-Cohen Y; Goldberg Z; Zuckerman V; Grossman T; Haupt S; Haupt Y
Biochem Biophys Res Commun; 2005 Jun; 331(3):737-49. PubMed ID: 15865930
[TBL] [Abstract][Full Text] [Related]
39. E3 ubiquitin ligase E6AP-mediated TSC2 turnover in the presence and absence of HPV16 E6.
Zheng L; Ding H; Lu Z; Li Y; Pan Y; Ning T; Ke Y
Genes Cells; 2008 Mar; 13(3):285-94. PubMed ID: 18298802
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.
Mantovani F; Banks L
Oncogene; 1999 Jun; 18(22):3309-15. PubMed ID: 10362351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
